A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 6, 2009, Pages 1083-1090

  Lee, Jae Jin ^a   Kim, Si Young ^j   Chung, Hyun Cheol ^b   Lee, Kyung Hee ^c   Song, Hong Suk ^d   Kang, Won Ki ^e   Hong, Young Seon ^f   Choi, In Sil ^g   Lee, Young Yeul ^h   Woo, In Sook ^f   Choi, Jin Hyuk ⁱ  

^a Kyung Hee University Hospital   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Yeungnam University Hospital   (South Korea)

^d Dongsan Medical Center   (South Korea)

^e Samsung Medical Center   (South Korea)

^f The Catholic University of Korea   (South Korea)

^g Seoul National University Boramae Hospital   (South Korea)

^h Hanyang University   (South Korea)

ⁱ Ajou University Medical Center   (South Korea)

^j Kyung Hee University College of Medicine   (South Korea)

more..

Author keywords

Advanced gastric cancer; Chemotherapy; First line; Paclitaxel; Phase II; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; RANITIDINE;

ABDOMINAL PAIN; ADD ON THERAPY; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DISEASE DURATION; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERBILIRUBINEMIA; INFECTION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RECURRENT CANCER; SIDE EFFECT; STOMACH CANCER; STOMACH HEMORRHAGE; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; OXONIC ACID; PACLITAXEL; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; TEGAFUR;

EID: 63949083024     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0818-3     Document Type: Article

References (25)

1. JA Ajani DH Ilson DP Kelsen 1996 Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas Semin Oncol 23 55 58
2. JA Ajani FC Lee DA Singh DG Haller HJ Lenz AB Benson 3rd R Yanagihara AT Phan JC Yao D Strumberg 2006 Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma J Clin Oncol 24 663 667
3. P Chollet P Schoffski K Weigang-Kohler JH Schellens H Cure N Pavlidis V Grunwald R De Boer J Wanders P Fumoleau 2003 Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG) Eur J Cancer 39 1264 1270
4. QS Chu LA Hammond G Schwartz L Ochoa SY Rha L Denis K Molpus B Roedig SP Letrent B Damle AP DeCillis EK Rowinsky 2004 Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies Clin Cancer Res 10 4913 4921
5. M D'Angelica M Gonen MF Brennan AD Turnbull M Bains MS Karpeh 2004 Patterns of initial recurrence in completely resected gastric adenocarcinoma Ann Surg 240 808 816
6. K Fujitani H Narahara H Takiuchi T Tsujinaka E Satomi M Gotoh M Hirao H Furukawa T Taguchi 2005 Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer Oncology 69 414 420
7. Y Fujiwara J Fujita K Kan K Tsukahara S Takiguchi H Miyata T Yasuda Y Doki M Monden 2006 A phase I study of combination chemotherapy using TS-1 and weekly paclitaxel for advanced gastric cancer Gan To Kagaku Ryoho 33 45 48
8. PM Hoff ED Saad JA Ajani Y Lassere C Wenske D Medgyesy S Dwivedy M Russo R Pazdur 2003 Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors Clin Cancer Res 9 134 142
9. S Hokita T Aikou F Miyazono S Ishigami K Aridome S Maenohara T Saihara K Suenaga H Nomura S Maeda H Takatori H Arima Y Uchikado S Natsugoe S Takao 2006 A phase I combination chemotherapy study of biweekly paclitaxel and S-1 administration in patients with advanced gastric cancer Cancer Chemother Pharmacol 57 736 740
10. A Jemal RC Tiwari T Murray A Ghafoor A Samuels E Ward EJ Feuer MJ Thun 2004 Cancer statistics, 2004 CA Cancer J Clin 54 8 29
11. HC Jeung SY Rha HK Kim HY Lim S Kim SY Kim SJ Gong CH Park JB Ahn SH Noh HC Chung 2007 Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations Oncologist 12 543 554
12. Y Kano M Akutsu S Tsunoda J Ando J Matsui K Suzuki T Ikeda Y Inoue K Adachi 1996 Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro Br J Cancer 74 704 710
13. R Kawabata Y Fujiwara Y Doki J Fujita Y Tsukahara M Yamasaki H Miyata S Takiguchi M Monden 2007 Phase I/II study of a combination of S-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer Oncology 72 219 225
14. W Koizumi M Kurihara S Nakano K Hasegawa 2000 Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group Oncology 58 191 197
15. W Koizumi H Narahara T Hara A Takagane T Akiya M Takagi K Miyashita T Nishizaki O Kobayashi W Takiyama Y Toh T Nagaie S Takagi Y Yamamura K Yanaoka H Orita M Takeuchi 2008 S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 215 221
16. Gotro Korea (2002) Annual report on the cause of death statistics, 2001. Korea National Statistical Office, Daejeon
17. E Mochiki T Ohno Y Kamiyama R Aihara N Haga H Ojima J Nakamura H Ohsawa T Nakabayashi K Takeuchi T Asao H Kuwano 2006 Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer Br J Cancer 95 1642 1647
18. AM Murad A Petroianu RC Guimaraes BC Aragao LO Cabral AO Scalabrini-Neto 1999 Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen Am J Clin Oncol 22 580 586
19. N. Boku SY, Shirao, K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Kimura A, Ohtsu A, Gastrointestinal Oncology Study Group/Japan Clinical Oncology Group (2007) Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. 25;18S:LBA4513
20. Nakajo A, Hokita S, Ishigami S, Miyazono F, Etoh T, Hamanoue M, Maenohara S, Iwashita T, Komatsu H, Satoh K, Aridome K, Morita S, Natsugoe S, Takiuchi H, Nakano S, Maehara Y, Sakamoto J, Aikou T (2008) A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer. Cancer Chemother Pharmacol
21. Y Sakata A Ohtsu N Horikoshi K Sugimachi Y Mitachi T Taguchi 1998 Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1715 1720
22. K Sugimachi Y Maehara N Horikoshi Y Shimada Y Sakata Y Mitachi T Taguchi 1999 An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group Oncology 57 202 210
23. Y Ueda H Yamagishi D Ichikawa J Morii K Koizumi N Kakihara M Shimotsuma A Takenaka T Yamashita H Kurioka M Nishiyama S Morita K Nakamura J Sakamoto 2005 Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer Oncology 69 261 268
24. J Wils 1996 The treatment of advanced gastric cancer Semin Oncol 23 397 406
25. K Yoshida M Ninomiya N Takakura N Hirabayashi W Takiyama Y Sato S Todo M Terashima M Gotoh J Sakamoto M Nishiyama 2006 Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer Clin Cancer Res 12 3402 3407